Q4 2024 Almirall SA Earnings Call Transcript
Key Points
- Almirall SA (LBTSF) surpassed its 2024 guidance, achieving double-digit net sales growth and an EBITDA of EUR192.6 million, exceeding the anticipated range.
- The company has positioned itself well in the growing medical dermatology market, with key products like Ilumetri and EBGLYSS driving significant growth.
- Almirall SA (LBTSF) has a strong R&D pipeline, with plans to initiate four proof of concept clinical studies in the next 15 months.
- The European dermatology segment showed robust performance with a 22.5% year-on-year growth, driven by biologics and other derm products.
- The company maintains a favorable net debt to EBITDA ratio of 0.2 times, allowing for potential licensing or bolt-on M&A opportunities.
- Almirall SA (LBTSF) faces gross margin pressure due to increased royalty tiers, particularly from Ilumetri, as sales increase.
- The US legacy business remains under pressure from ongoing generic competition, impacting products like Cordran and Tazorac.
- R&D investments are consuming a substantial portion of resources, maintaining a high level of 12.6% of net sales.
- The company anticipates continued gross margin pressure in the coming years due to the sales mix and higher royalty tiers.
- There is uncertainty regarding the impact of biosimilars entering the psoriasis market, which could affect the growth of Ilumetri.
Good day and thank you for standing by. Welcome to the Almirall full year 2024 results and business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would like to hand the conference over to the first speaker today, Pablo Divasson. Please go ahead.
Thank you very much, Nadia. Good morning, everyone. Thank you for joining us for today's quarterly earnings update and review of Almirall's 2024 full year financial results. As always, we are sharing the slides we are using today in the investor section of our website at almirall.com.
Please move to a slide number 2. Let me remind you that the information presented in this call contains forward-looking statements, which involve known and unknown risk, uncertainties, and other factors that may cause actual results to materially differ from what we are sharing today.
Please move to lane number 3. Presenting today, we have Carlos Gallardo, Chairman and Chief Executive Officer; Mike
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
